Pyrotinib Targeted EGFR-STAT3/CD24 Loop-Mediated Cell Viability in TSC.

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Tuberous Sclerosis Complex (TSC) is a genetic disorder characterized by abnormal cell growth.
• TSC2-deficient cells exhibit uncontrolled proliferation and altered signaling pathways.
• Current therapeutic options for TSC have limitations.

Purpose of the Study:

• To investigate the efficacy of pyrotinib, a pan-ErbB receptor tyrosine kinase inhibitor, against TSC2-deficient cells.
• To elucidate the molecular mechanisms underlying pyrotinib's action in TSC models.
• To evaluate pyrotinib as a potential therapeutic agent for TSC.

Main Methods:

• In vitro and in vivo studies using TSC2-deficient and TSC2-expressing cells.
• Assessment of cell viability, proliferation, and apoptosis.
• Analysis of EGFR, STAT3, and CD24 signaling pathways, including protein import and promoter binding.

Main Results:

• Pyrotinib significantly inhibited the viability of TSC2-deficient cells while having a limited effect on TSC2-expressing cells.
• Pyrotinib induced G1-phase cell cycle arrest and apoptosis in TSC2-deficient cells.
• Pyrotinib disrupted the EGFR-STAT3/CD24 signaling loop by inhibiting pEGFR nuclear import and boosting CD24 expression, with CD24 reciprocally enhancing pEGFR function.

Conclusions:

• Pyrotinib specifically targets and inhibits TSC2-deficient cells, offering a potential therapeutic strategy for TSC.
• The mechanism involves the disruption of the EGFR-STAT3/CD24 signaling loop.
• Pyrotinib demonstrates promise as a novel therapeutic drug for Tuberous Sclerosis Complex treatment.